Capecitabine, Irinotecan, Oxaliplatin (CAPIRINOX) and Concomitant Irradiation in Advanced Rectal Cancer: The Lyon R-02-01 Phase I Trial

A treatment associating radiotherapy (46 Gy + 4 Gy) with concomitant chemotherapy comprising capecitabine (1500 mg/m2/day, every day) and irinotecan (50 mg/m2/week, for 5 weeks) was feasible and well tolerated. The addition of oxaliplatin to these doses was prohibitory to the continuation of treatment due to unacceptable toxicity.